Critical Assessment of Myelography Practices: A Call for Rational Guideline Revision

References

1. 1.↵
   ACR-ASNR Practice Guideline for the Performance of Myelography and Cisternography 2013. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Myelog-Cisternog.pdf. Accessed October 4, 2018.
2. 2.↵
   ACR-ASNR Practice Guideline for the Performance of Myelography and Cisternography 2018. In press.
3. 3.↵
   OMNIPAQUE (iohexol) Injection by General Electric Healthcare. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018956s099lbl.pdf. Accessed August 23, 2018.
4. 4.↵
   ISOVUE-M (iopamidol) Injection. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018735s057lbl.pdf. Accessed August 23, 2018.
5. 5.↵
   2. Ahmed I,
   3. Pepple R,
   4. Jones RP

   . Absence status epilepticus resulting from metrizamide and Omnipaque myelography. Clin Electroencephalogr 1988;19:37–42 doi:10.1177/155005948801900110 pmid:3396204

   CrossRefPubMed
6. 6.↵
   2. Alimohammadi H,
   3. Abdalvand A,
   4. Safari S, et al

   . Status epilepticus after myelography with iohexol (Omnipaque). Am J Emerg Med 2012;30:2092.e1–3 doi:10.1016/j.ajem.2011.12.034 pmid:22386347

   CrossRefPubMed
7. 7.↵
   2. Altschuler EM,
   3. Segal R

   . Generalized seizures following myelography with iohexol (Omnipaque). J Spinal Disord 1990;3:59–61 pmid:2134411

   PubMed
8. 8.↵
   2. Baccarini L,
   3. de Nicola D,
   4. Gasaprini D, et al

   . lopamidol (B 15000), a nonionic water-soluble contrast medium for neuroradiology, Part I: results of a clinical trial for myelography. Neuroradiology 1982;23:81–84 doi:10.1007/BF00367241 pmid:7043305

   CrossRefPubMed
9. 9.↵
   2. Baker RA,
   3. Hillman BJ,
   4. McLennan JE, et al

   . Sequelae of metrizamide myelography in 200 examinations. AJR Am J Roentgenol 1978;130:499–502 doi:10.2214/ajr.130.3.499 pmid:415557

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Bassi P,
    3. Cecchini A,
    4. Dettori P, et al

    . Myelography with iopamidol, a nonionic water-soluble contrast medium: incidence of complications. Neuroradiology 1982;24:85–90 doi:10.1007/BF00339196 pmid:7177375

    CrossRefPubMed
11. 11.↵
    2. Bertoni JM,
    3. Schwartzman RJ,
    4. Van Horn G, et al

    . Asterixis and encephalopathy following metrizamide myelography: investigations into possible mechanisms and review of the literature. Ann Neurol 1981;9:366–70 doi:10.1002/ana.410090409 pmid:7224601

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Butler MJ,
    3. Cornell SH,
    4. Damasio AR

    . Aphasia following pluridirectional tomography with metrizamide: the effect of patient position. Arch Neurol 1985;42:39–45 doi:10.1001/archneur.1985.04060010045014 pmid:3966883

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Carchietti E,
    3. Baldassarre M,
    4. Penco T, et al

    . Iopamidol 300-induced epilepsy: intensive treatment and pathogenic hypothesis. Neuroradiology 1988;30:256–57 doi:10.1007/BF00341838 pmid:3405414

    CrossRefPubMed
14. 14.↵
    2. Carella A,
    3. Federico F,
    4. Di Cuonzo F, et al

    . Adverse side effects of metrizamide and iopamidol in myelography. Neuroradiology 1982;22:247–49 doi:10.1007/BF00342072 pmid:6174896

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Dalen K,
    3. Kerr HH,
    4. Wang AM, et al

    . Seizure activity after iohexol myelography. Spine (Phila Pa 1976) 1991;16:384 doi:10.1097/00007632-199103000-00028 pmid:2028320

    CrossRefPubMed
16. 16.↵
    2. Drayer BP,
    3. Vassallo C,
    4. Sudilovsky A, et al

    . A double-blind clinical trial of iopamidol versus metrizamide for lumbosacral myelography. J Neurosurg 1983;58:531–37 doi:10.3171/jns.1983.58.4.0531 pmid:6338167

    CrossRefPubMed
17. 17.↵
    2. Hindmarsh T,
    3. Grepe A,
    4. Widen L

    . Metrizamide-phenothiazine interaction: report of a case with seizures following myelography. Acta Radiol Diagn (Stockh) 1975;16:129–34 doi:10.1177/028418517501600204 pmid:810000

    CrossRefPubMed
18. 18.↵
    2. Killebrew K,
    3. Whaley RA,
    4. Hayward JN, et al

    . Complications of metrizamide myelography. Arch Neurol 1983;40:78–80 doi:10.1001/archneur.1983.04050020040007 pmid:6824454

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Klein KM,
    3. Shiratori K,
    4. Knake S, et al

    . Status epilepticus and seizures induced by iopamidol myelography. Seizure 2004;13:196–99 doi:10.1016/S1059-1311(03)00077-3 pmid:15010060

    CrossRefPubMed
20. 20.↵
    2. Levey AI,
    3. Weiss H,
    4. Yu R, et al

    . Seizures following myelography with iopamidol. Ann Neurol 1988;23:397–99 doi:10.1002/ana.410230416 pmid:3382176

    CrossRefPubMed
21. 21.↵
    2. Lipman JC,
    3. Wang AM,
    4. Brooks ML, et al

    . Seizure after intrathecal administration of iopamidol. AJNR Am J Neuroradiol 1988;9:787–88 pmid:3135723

    FREE Full Text
22. 22.↵
    2. Maly P,
    3. Bach-Gansmo T,
    4. Elmqvist D

    . Risk of seizures after myelography: comparison of iohexol and metrizamide. AJNR Am J Neuroradiol 1988;9:879–83 pmid:3140631

    Abstract/FREE Full Text
23. 23.↵
    2. Maly P,
    3. Olivecrona H,
    4. Almén T, et al

    . Interaction between chlorpromazine and intrathecally injected non-ionic contrast media in non-anaesthetized rabbits. Neuroradiology 1984;26:235–40 doi:10.1007/BF00342420 pmid:6547514

    CrossRefPubMed
24. 24.↵
    2. Noda K,
    3. Miyamoto K,
    4. Beppu H, et al

    . Prolonged paraplegia after iohexol myelography. Lancet 1991;337:681 pmid:1672026

    PubMed
25. 25.↵
    2. Singh S,
    3. Rajpal C,
    4. Nannapeneni S, et al

    . Iopamidol myelography-induced seizures. MedGenMed 2005;7:11 pmid:16369390

    PubMed
26. 26.↵
    2. Tahta K,
    3. Ozgen T,
    4. Berker M, et al

    . Status epilepticus following iohexol myelography. Neuroradiology 1993;35:322–23 doi:10.1007/BF00602626 pmid:8492906

    CrossRefPubMed
27. 27.↵
    2. Vossler DG,
    3. Wright SJ Jr.

    . Convulsive status epilepticus following intrathecal iopamidol administration. J Epilepsy 1994;7:18–20 doi:10.1016/0896-6974(94)90113-9

    CrossRef
28. 28.↵
    2. Hanus PM

    . Metrizamide: a review with emphasis on drug interactions. Am J Hosp Pharm 1980;37:510–13 pmid:6103672

    Abstract
29. 29.↵
    2. Maimaiti NRA,
    3. Aghaie LA

    . Economic impact of surgery cancellation in a general hospital, Iran. Ethiopian Journal of Health Development https://www.ajol.info/index.php/ejhd/article/view/167749. Accessed August 23, 2018.
30. 30.↵
    2. Pepe MS

    . The Statistical Evaluation of Medical Tests for Classification and Prediction. New York: Oxford University Press; 2003
31. 31.↵
    2. Skalpe IO,
    3. Amundsen P

    . Thoracic and cervical myelography with metrizamide: clinical experiences with a water-soluble, non-ionic contrast medium. Radiology 1975;116:101–06 doi:10.1148/116.1.101 pmid:1138257

    CrossRefPubMed
32. 32.↵
    2. Skalpe IO,
    3. Amundsen P

    . Lumbar radiculography with metrizamide: a nonionic water-soluble contrast medium. Radiology 1975;115:91–95 doi:10.1148/115.1.91 pmid:1118625

    CrossRefPubMed
33. 33.↵
    2. Junck L,
    3. Marshall WH

    . Neurotoxicity of radiological contrast agents. Ann Neurol 1983;13:469–84 doi:10.1002/ana.410130502 pmid:6347033

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Centeno RS,
    3. Sovak M,
    4. Hackney DB, et al

    . Brain changes on computed tomography following metrizamide myelography: significance and therapeutic implications. Spine (Phila Pa 1976) 1986;11:509–12 doi:10.1097/00007632-198607000-00001 pmid:3787318

    CrossRefPubMed
35. 35.↵
    2. Drayer BP,
    3. Rosenbaum AE

    . Metrizamide brain penetrance. Acta Radiol Suppl 1977;355:280–93 pmid:299673

    PubMed
36. 36.↵
    2. Ropper AH,
    3. Chiappa KH,
    4. Young RR

    . The effect of metrizamide on the electroencephalogram: a prospective study in 61 patients. Ann Neurol 1979;6:222–26 doi:10.1002/ana.410060308 pmid:534420

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Caillé JM,
    3. Guibert-Tranier F,
    4. Howa JM, et al

    . Cerebral penetration following metrizamide myelography [in French]. J Neuroradiol 1980;7:3–12 pmid:7229684

    PubMed
38. 38.↵
    2. Solti-Bohman L,
    3. Bentson JR

    . Comparative advantages of small- and large-dose metrizamide myelography. AJR Am J Roentgenol 1983;141:825–28 doi:10.2214/ajr.141.4.825 pmid:6604437

    CrossRefPubMed
39. 39.↵
    2. Ekholm SE,
    3. Reece K,
    4. Coleman JR, et al

    . Metrizamide: a potential in vivo inhibitor of glucose metabolism. Radiology 1983;147:119–21 doi:10.1148/radiology.147.1.6828715 pmid:6828715

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Steiner E,
    3. Simon JH,
    4. Ekholm SE, et al

    . Neurologic complications in diabetics after metrizamide lumbar myelography. AJR Am J Roentgenol 1986;146:1057–60 doi:10.2214/ajr.146.5.1057 pmid:3485900

    CrossRefPubMed
41. 41.↵
    2. Skalpe IO

    . Adverse effects of water-soluble contrast media in myelography, cisternography and ventriculography: a review with special reference to metrizamide. Acta Radiol Suppl 1977;355:359–70 pmid:400906

    PubMed
42. 42.↵
    2. Meador K,
    3. Hamilton WJ,
    4. El Gammal TA, et al

    . Irreversible neurologic complications of metrizamide myelography. Neurology 1984;34:817–21 doi:10.1212/WNL.34.6.817 pmid:6539448

    Abstract/FREE Full Text
43. 43.↵
    2. Maly P,
    3. Sundgren P,
    4. Bååth L, et al

    . Neural tolerance of the non-ionic dimers iodixanol and iotrolan and the non-ionic monomer iopamidol during myelography in non-anaesthetised rabbits. Acta Radiol 1995;36:644–48 pmid:8519577

    CrossRefPubMed
44. 44.↵
    2. La Noce A,
    3. Bertani F,
    4. Lorusso V, et al

    . Preclinical safety assessment of iomeprol for injection as contrast medium for myelography. Eur J Radiol 1994;18(Suppl 1):S43–50 doi:10.1016/0720-048X(94)90093-0 pmid:8020518

    CrossRefPubMed
45. 45.↵
    2. Gonsette RE,
    3. Brucher JM

    . Neurotoxicity of novel water-soluble contrast media for intrathecal application. Invest Radiol 1980;15:S254–59 doi:10.1097/00004424-198011001-00054 pmid:6894139

    CrossRefPubMed
46. 46.↵
    2. Sundgren P,
    3. Bååth L,
    4. Maly P

    . CNS-effects from subarachnoid injections of iohexol and the non-ionic dimers iodixanol and iotrolan in the rabbit. Acta Radiol 1995;36:307–11 pmid:7742128

    CrossRefPubMed
47. 47.↵
    2. Witwer G,
    3. Cacayorin ED,
    4. Bernstein AD, et al

    . Iopamidol and metrizamide for myelography: prospective double-blind clinical trial. AJR Am J Roentgenol 1984;143:869–73 doi:10.2214/ajr.143.4.869 pmid:6382981

    CrossRefPubMed
48. 48.↵
    2. Fedutes BA,
    3. Ansani NT

    . Seizure potential of concomitant medications and radiographic contrast media agents. Ann Pharmacother 2003;37:1506–10 doi:10.1345/aph.1C464 pmid:14519049

    CrossRefPubMed
49. 49.↵
    2. Sandow BA,
    3. Donnal JF

    . Myelography complications and current practice patterns. AJR Am J Roentgenol 2005;185:768–71 doi:10.2214/ajr.185.3.01850768 pmid:16120932

    CrossRefPubMed
50. 50.↵
    2. Olsen J

    . Seizures after myelography with iopamidol. Am J Emerg Med 1994;12:329–30 doi:10.1016/0735-6757(94)90151-1 pmid:8179742

    CrossRefPubMed
51. 51.↵
    2. Nakstad P,
    3. Helgetveit A,
    4. Aaserud O, et al

    . Iohexol compared to metrizamide in cervical and thoracic myelography: a randomized double blind parallel study. Neuroradiology 1984;26:479–84 doi:10.1007/BF00342685 pmid:6390248

    CrossRefPubMed
52. 52.↵
    2. Lin SM,
    3. Tsou MY,
    4. Chan KH, et al

    . Myoclonic seizure in the postanesthesia care unit after thoracic laminectomy. Anesth Analg 2002;95:777–79, table of contents pmid:12198071

    PubMed
53. 53.↵
    2. Aldred B,
    3. Pierson N,
    4. Shah L

    . Selective discontinuation of medications prior to myelography: Is it really necessary? American Society of Spine Radiology, February 23–26, 2017; San Diego, CA. Abstract
54. 54.↵
    2. Grunert P,
    3. Pendl G

    . Cerebral seizure following lumbar myelography with iopamidol [in German]. Radiologe 1986;26:526–27 pmid:3101135

    PubMed
55. 55.↵
    2. Maly P,
    3. Almén T,
    4. Golman K, et al

    . Excitative effects in anaesthetized rabbits from subarachnoidally injected iso- and hyperosmolar solutions of iohexol and metrizamide. Neuroradiology 1984;26:131–36 doi:10.1007/BF00339861 pmid:6717791

    CrossRefPubMed
56. 56.↵
    2. Golman K,
    3. Olivecrona H,
    4. Gustafson C, et al

    . Excitation and depression of non-anaesthetized rabbits following injection of contrast media into the subarachnoid space. Acta Radiol Suppl 1980;362:83–86 pmid:6267897

    PubMed
57. 57.↵
    2. Sovak M,
    3. Ranganathan R,
    4. Kerber CW, et al

    . Iotrol, a new myelographic agent, 2: comparative electroencephalographic evaluation by spectrum analysis. AJNR Am J Neuroradiol 1983;4:319–22 pmid:6410733

    Abstract/FREE Full Text
58. 58.↵
    2. Hauge O,
    3. Falkenberg H

    . Neuropsychologic reactions and other side effects after metrizamide myelography. AJR Am J Roentgenol 1982;139:357–60 doi:10.2214/ajr.139.2.357 pmid:6979893

    CrossRefPubMedWeb of Science
59. 59.↵
    2. Standnes B,
    3. Oftedal SI,
    4. Weber H

    . Effect of levomepromazine on EEG and on clinical side effects after lumbar myelography with metrizamide. Acta Radiol Diagn (Stockh) 1982;23:111–14 doi:10.1177/028418518202300205 pmid:7090846

    CrossRefPubMed
60. 60.↵
    2. Gonsette RE,
    3. Liesenborghs L

    . Iohexol: a new nonionic contrast medium for myelography and cisternography with markedly reduced neurotoxicity. Invest Radiol 1985;20:S32–36 pmid:3871751

    PubMed
61. 61.↵
    2. Smith RR

    . Myelographic complications associated with drug interactions. AJR Am J Roentgenol 2001;177:713 pmid:11517082

    PubMed
62. 62.↵
    2. Eames FA,
    3. Cloft HJ

    . Discontinuing patient medications prior to myelography. AJR Am J Roentgenol 2005;184:695 pmid:15671403

    PubMed
63. 63.↵
    2. Howland RH

    . Potential adverse effects of discontinuing psychotropic drugs, Part 3: antipsychotic, dopaminergic, and mood-stabilizing drugs. J Psychosoc Nurs Ment Health Serv 2010;48:11–14 doi:10.3928/02793695-20100708-01 pmid:20669865

    CrossRefPubMed
64. 64.↵
    2. Fincham JE

    . Response rates and responsiveness for surveys, standards, and the journal. Am J Pharm Educ 2008;72:43 doi:10.5688/aj720243 pmid:18483608

    CrossRefPubMed
65. 65.↵
    2. Nulty DD

    . The adequacy of response rates to online and paper surveys: what can be done? Assessment & Evaluation in Higher Education 2008;33:301–14 doi:10.1080/02602930701293231

    CrossRef
66. 66.
    2. Canbay O,
    3. Bal N,
    4. Akinci S, et al

    . Rhabdomyolysis after intraoperative myelography. Paediatr Anaesth 2004;14:509–13

    PubMed
67. 67.
    2. Kelley BC,
    3. Roh S,
    4. Johnson PL, et al

    . Malignant cerebral edema following CT myelogram using Isovue-M 300 intrathecal nonionic water-soluble contrast: a case report. Radiol Res Pract 2011;2011:212516

    PubMed
68. 68.
    2. Sobel DF,
    3. Rowe R,
    4. Zyroff J, et al

    . Adverse reactions to iopamidol and iohexol myelography with special attention to headache: role of myelographic technique. Headache 1989;29:519–22

    PubMed
69. 69.
    2. Teasdale E,
    3. Macpherson P

    . Guidelines for cervical myelography: lumbar versus cervical puncture technique. Br J Radiol 1984;57:789–93

    Abstract/FREE Full Text